Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395278 · ClinicalTrials.gov registry record
Development of Serologic Assays for Human Herpes Virus-8
A clinical trial of HIV Infection and Kaposi Sarcoma, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 394
- Enrollment target
- 1
- Study location
NCT00395278 is a study of HIV Infection and Kaposi Sarcoma that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 394 participants, above the 237-participant average among 73 other HIV Infection trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00395278, a study of HIV Infection and Kaposi Sarcoma, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 394 participants
- Enrollment target
- 1
- Study location
Study Summary
Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2006-10-30 |
| Est. Completion | 2020-12-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395278
The ClinicalTrials.gov registry entry for NCT00395278 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 237-participant average among 73 other HIV Infection trials with a reported enrollment target (66% higher). The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT00395278 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00395278 about?
NCT00395278 is a clinical study titled "Development of Serologic Assays for Human Herpes Virus-8". Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of K...
What is the current status of trial NCT00395278?
This trial is currently completed. The enrollment target is 394 participants. The study started on 2006-10-30. Estimated completion is 2020-12-10.
What conditions does trial NCT00395278 study?
This clinical trial studies the following conditions: HIV Infection, Kaposi Sarcoma.
Who is sponsoring clinical trial NCT00395278?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00395278 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
RECRUITING · NA
-
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
RECRUITING · NA
-
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.